Results 131 to 140 of about 70,663 (209)

Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspective. [PDF]

RMD Open
Hsieh EWY, Chung JB, Amin A, Askanase AD, Bartok B, Brunetta P, Carrasco-Alfonso MJ, Coney C, Cooper JC, Dall'Era M, Delev N, Eldred A, Furie RA, Garces S, Groover K, Harrington M, Hogan JJ, Imperato GH, Jackson M, Jackson SW, Jongco AM, Karis E, Koegel A, König MF, Koretzky G, Kumar V, Morand E, Payne AS, Popat V, Rizvi N, Rohan P, Sadelain M, Schett G, Singh AP, van Vollenhoven RF, Zack D, Lupus ABC CAR T Working Group.   +36 more
europepmc   +1 more source

Camelid immunoglobulins and nanobody technology [PDF]

, 2009
Baral, TN, De Baetselier, P, De Genst, E, Hassanzadeh-Ghassabeh, G, Kinne, J, Leonhardt, H, Magez, Stefan, Muyldermans, S, Nguyen, VK, Retarnozzo, VC, Revets, H, Rothbauer, U, Saerens, D, Stijemans, B, Tillib, S, Wernery, U, Wyns, L   +16 more
core   +1 more source

The CXCL16/CXCR6 axis is linked to immune effector cell-associated neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. [PDF]

Genome Med
Lu IN, Müller-Miny L, Krekeler C, Cheung PF, Antonopoulou G, Jeibmann A, Schulte-Mecklenbeck A, Kerl K, Call S, Reicherts C, Bleckmann A, Stelljes M, Lenz G, Wiendl H, Meyer Zu Hörste G, Grauer OM.   +15 more
europepmc   +1 more source

Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy. [PDF]

Immunooncol Technol
Carcopino C, Erdogan E, Henrich M, Kobold S.   +3 more
europepmc   +1 more source

Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breast- and pancreatic cancer in vitro and in a murine xenograft model of ovarian cancer. [PDF]

Cancer Cell Int
Boulifa A, Franzén AS, Raftery MJ, Radecke C, Pecher G.   +4 more
europepmc   +1 more source

Identification of Hub Genes and Pathways in Preinfusion Chimeric Antigen Receptor (CAR) T-cell Products Associated With Cytokine Release Syndrome. [PDF]

Cureus
Khalafallah SA, Mohammed Elzein A, Faris IM, Attaelmanan GA, Alamin MF, Almleeh A, Bader M, Alfaki M.   +7 more
europepmc   +1 more source

La dolce vita: fueling chimeric antigen receptor (CAR) T cells with Glut1 to improve therapeutic efficacy. [PDF]

Immunometabolism (Cobham)
Slattery K, Finlay DK, Darcy PK.
europepmc   +1 more source

Safety and Efficacy of CD19-Targeted Chimeric Antigen Receptor (CAR) T-cells Generated Using DNA Transposon Systems: A Meta-Analysis. [PDF]

Cureus
Rajput A, Sajjad SA, Kumar A, Singh K.
europepmc   +1 more source

Chimeric Antigen Receptor (CAR) T Cells Releasing Soluble SLAMF6 Isoform 2 Gain Superior Anti-Cancer Cell Functionality in an Auto-Stimulatory Fashion. [PDF]

Cells
Harrer DC, Schlierkamp-Voosen T, Barden M, Pan H, Xydia M, Herr W, Dörrie J, Schaft N, Abken H.   +8 more
europepmc   +1 more source

Association of CD19⁺-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortality. [PDF]

J Allergy Clin Immunol
Sutherland NM, Zhou B, Zhang L, Ong MS, Hong JS, Pak A, Liu KJ, Frigault MJ, Maus MV, Hill JA, Reynolds K, Walter JE, Camargo CA, Barmettler S.   +13 more
europepmc   +1 more source